FABRIC GENOMICS INC.

Company Overview

Fabric Genomics Inc. (formerly known as Omicia Inc.) provides software for interpreting genome data. The company’s platform product is Opal, which is a clinical genomics package for precision medicine applications. Opal is a web-accessible software package that allows clinicians to analyze genomes by characterizing disease-causing variants. Opal is designed for both clinical researchers and CLIA labs.

Fabric has been a key provider of NGS interpretation services to the U.K.’s 100,000 Genomes Project.

In January 2017, the then-Omicia acquired Spiral Genetics, which strengthened the company’s secondary NGS analysis and structural variant expertise. The acquisition increased the firm’s profile in the clinical NGS field, by enabling it to offer a wider range of abilities on a single software platform.

Fabric Genomics’ tools allow for better clinical diagnosis. For example, the Phenotype-Driven Variant Ontological Re-ranking tool (Phevor) is able to use a patient’s phenotype and genomic data to come up with a diagnosis.

In October 2020, Fabric Genomics formed a strategic alliance with Roche to co-market whole-exome sequencing products and services for hereditary genetics. The companies agreed to promote Roche’s research-use-only Kapa HyperExome Probe together with Fabric’s Enterprise bioinformatics and analysis platform.

Company's Business Segments

• Products : The company generates revenue fro several products such as Panel Interpretation, WGS/WES Interpretation, Clinical Services, Fabric Enterprise Platform, Broad Institute $1K Clinical WGS, Hereditary Risk Screening, Rare Disease Diagnosis, Rapid NICU Testing, Pediatric Panels, Country Genome Projects